NASH/MASH Treatment Market Set for Explosive Growth to US$ 33.02 Billion by 2033, Led by North America's 79.1% Market Share | Key Players - Novo Nordisk A/S, Boehringer Ingelheim International GmbH., Akero Therapeutics, Inc.

The Global NASH/MASH Treatment Market reached US$ 8.13 billion in 2025 and is expected to reach US$ 33.02 billion by 2033, growing at a CAGR of 17.55% during the forecast period 2026-2033.

The market is witnessing substantial growth as the global burden of obesity, type 2 diabetes, metabolic syndrome, and liver-related disorders continues to rise significantly across both developed and emerging economies. Increasing awareness regarding early diagnosis, expanding clinical research activities, and strong regulatory focus on advanced liver disease therapies are further accelerating the adoption of innovative NASH/MASH treatment solutions worldwide.

Industry participants are increasingly focusing on the development of targeted therapeutics, combination therapies, and precision medicine approaches to improve treatment efficacy and long-term patient outcomes. Strategic collaborations between pharmaceutical companies, biotechnology firms, and research organizations are also strengthening drug development pipelines, while growing investments in late-stage clinical trials and AI-driven drug discovery platforms are expected to create long-term commercial opportunities across the global NASH/MASH treatment landscape.

Request Executive Sample Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/nash-or-mash-treatment-market?ram

Key Industry Developments

United States:
✅ January 2026: Sagimet Biosciences announced new Phase IIb FASCINATE-2 data for denifanstat at the MASH-TAG Conference, highlighting anti-fibrotic effects in advanced F3 and qFibrosis stage 4 MASH patients. The findings strengthened the drug's potential as a next-generation therapy targeting liver fibrosis progression.

✅ November 2025: Akero Therapeutics presented additional analyses from its Phase IIb SYMMETRY and HARMONY programs for efruxifermin (EFX) at The Liver Meeting (AASLD). The data further demonstrated fibrosis regression and validated the use of advanced digital pathology technologies for MASH assessment.

✅ August 2025: Novo Nordisk received U.S. FDA accelerated approval for Wegovy (semaglutide) for adults with MASH and moderate-to-advanced liver fibrosis. The approval made Wegovy the first GLP-1 receptor agonist authorized for MASH treatment, expanding therapeutic options beyond existing therapies.

Japan:
✅ May 2026: Novo Nordisk presented new clinical evidence on semaglutide for MASH at the EASL Congress 2026, including data relevant to Japanese patients. The company emphasized its commitment to expanding evidence-based MASH treatment access and improving early diagnosis strategies in Japan.

✅ August 2025: Novo Nordisk confirmed that, following the U.S. approval of Wegovy for MASH, regulatory submissions were progressing in Japan. The development marked a significant step toward introducing the first GLP-1-based MASH therapy to the Japanese market.

✅ October 2025: Takeda Pharmaceutical and other leading MASH stakeholders highlighted advancements in non-invasive biomarkers, patient-centric clinical trial designs, and novel therapeutic mechanisms at major MASH-focused industry forums. These efforts support the development of next-generation treatments tailored to the growing burden of MASH in Japan.

Strategic Acquisitions & Partnerships
✅ Madrigal Pharmaceuticals - Partnership / Global Licensing Agreement
(February 2026)
Madrigal Pharmaceuticals announced an exclusive global licensing agreement with Suzhou Ribo Life Science and Ribocure Pharmaceuticals for six preclinical siRNA programs targeting MASH. The deal expands Madrigal's pipeline beyond Rezdiffra and is intended to support the development of genetically targeted therapies and future combination treatments for MASH.

✅ Madrigal Pharmaceuticals - Partnership / Global Licensing Agreement
(July 2025)
Madrigal entered an exclusive global license agreement with CSPC Pharmaceutical Group for SYH2086, a preclinical oral GLP-1 receptor agonist. The agreement was designed to strengthen Madrigal's MASH franchise by exploring combination therapy opportunities with Rezdiffra and expanding its long-term pipeline.

Key Players:
Novo Nordisk A/S | Boehringer Ingelheim International GmbH. | 89bio, Inc. | Inventiva. | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD | Sagimet Biosciences. | Akero Therapeutics, Inc.

Key Highlights: Top 5 Key Players in NASH/MASH Treatment Market 2026
-Novo Nordisk A/S: Advanced the development and commercialization of GLP-1 based therapies for MASH, with Wegovy (semaglutide) demonstrating significant liver fibrosis improvement and metabolic benefits in late-stage clinical studies, strengthening the company's leadership in obesity-linked liver disease treatment.

-Boehringer Ingelheim International GmbH: Progressed survodutide, a dual glucagon/GLP-1 receptor agonist, through Phase II clinical development for MASH treatment, showing promising liver fat reduction and fibrosis improvement while targeting obesity and metabolic dysfunction simultaneously.

-89bio, Inc.: Expanded clinical development of pegozafermin, an FGF21 analog designed for MASH and severe hypertriglyceridemia, reporting strong Phase II trial outcomes with substantial reductions in liver fat, fibrosis markers, and triglyceride levels.

-Inventiva: Accelerated advancement of lanifibranor, a pan-PPAR agonist for MASH treatment, with Phase III NATiV3 trial progress focused on improving fibrosis and inflammation while addressing metabolic abnormalities associated with liver disease.

-Akero Therapeutics, Inc.: Strengthened its MASH pipeline with efruxifermin (EFX), an engineered FGF21 analog that demonstrated notable fibrosis reversal and NASH resolution in clinical studies, positioning the therapy as a potential best-in-class treatment candidate for advanced liver fibrosis.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/nash-or-mash-treatment-market?ram

Main Drivers and Trends Shaping the Future of the NASH/MASH Treatment Market
-Rising Disease Burden: The growing prevalence of obesity, type 2 diabetes, metabolic syndrome, and sedentary lifestyles is significantly increasing the global incidence of Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH), driving demand for effective therapies.

-Breakthrough Drug Approvals: The approval of Rezdiffra (resmetirom) as the first FDA-approved treatment for MASH and the expansion of GLP-1-based therapies such as semaglutide are transforming the treatment landscape and accelerating market growth.

-Pipeline Innovation: Pharmaceutical companies are investing heavily in next-generation therapies, including thyroid hormone receptor-beta agonists, GLP-1 receptor agonists, dual incretin therapies, and combination treatment approaches aimed at fibrosis regression and disease resolution.

-Precision Diagnostics & Early Detection: Advancements in non-invasive biomarkers, AI-assisted imaging, and fibrosis assessment tools are improving patient identification and treatment monitoring.

-Market Hurdles: High treatment costs, limited disease awareness, underdiagnosis, reimbursement challenges, and lengthy clinical development timelines remain key barriers to broader market adoption.

Regional Insights:
-North America: 79.1% (Largest share, driven by early commercialization of MASH therapies, high diagnosis rates, strong reimbursement systems, and the rapid adoption of approved treatments such as Rezdiffra in the U.S.)

-Europe: 11.0% (Supported by increasing awareness of metabolic liver diseases, expanding clinical research activities, and favorable healthcare infrastructure across major countries including Germany, France, Italy, Spain, and the U.K.)

-Asia Pacific: 7.0% (Fastest-growing region, fueled by a large patient pool, rising obesity and diabetes prevalence, and increasing healthcare investments across China, India, Japan, and South Korea.)

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=nash-or-mash-treatment-market?ram

Market Segmentation Analysis:
-By Drug: Resmetirom Leads as First Approved Therapy
Rezdiffra currently dominates attention in the market as the first FDA-approved treatment for MASH with fibrosis, driving strong physician adoption and commercial expansion.
Lanifibranor and Semaglutide are gaining momentum due to promising late-stage clinical outcomes in fibrosis improvement and metabolic control.
Emerging pipeline drugs such as Survodutide, Pegozafermin, Efruxifermin, and Denifanstat are advancing through trials, focusing on liver fat reduction, anti-fibrotic activity, and metabolic benefits.

-By Stage: Stage 2-3 Represents the Core Treatment Focus
Stage 2-3 patients form the primary treatment target due to significant fibrosis progression risk and eligibility for advanced therapeutic intervention.
Stage 0-1 cases are largely managed through lifestyle modification, weight management, and early metabolic control strategies.
Stage 4 disease, including cirrhosis-related complications, requires intensive monitoring, combination therapies, and in severe cases liver transplantation support.

-By Age Group: Adults Dominate Due to Rising Obesity and Diabetes
Adults account for the largest treatment demand owing to increasing obesity, type 2 diabetes, and sedentary lifestyles strongly linked to MASH development.
Geriatric patients represent a growing segment because aging populations face higher risks of fibrosis progression and chronic liver complications.
Pediatric cases are gradually increasing worldwide, mainly associated with childhood obesity and metabolic syndrome prevalence.

-By Gender: Male Population Shows Higher Disease Burden
Male patients represent a major treatment population due to higher incidence of obesity, insulin resistance, and fatty liver disorders linked to lifestyle-related risk factors.
Female cases are also rising steadily, especially among post-menopausal women where hormonal changes increase susceptibility to metabolic liver diseases.
Gender-specific clinical research is expanding to better understand disease progression patterns and treatment response variations.

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTW

Contact:
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to provide swift and astute solutions to clients like you. We encompass a multitude of syndicated reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.